Iovance Biotherapeutics Inc (LTS:0JDK)
$ 11.29 0.295 (2.68%) Market Cap: 3.48 Bil Enterprise Value: 3.15 Bil PE Ratio: 0 PB Ratio: 4.43 GF Score: 30/100

Q2 2021 Iovance Biotherapeutics Inc Earnings Call Transcript

Aug 05, 2021 / 08:30PM GMT
Release Date Price: $24.18 (+6.25%)
Operator

Welcome to the Iovance Biotherapeutics Second Quarter 2021 Financial Results. My name is Josh, and I will be your operator for today's call. (Operator Instructions). Please note that this conference is being recorded. I will now turn the call over to Sara Pellegrino, Vice President, Investor and Public Relations at Iovance. Sara, you may begin.

Sara Pellegrino
Iovance Biotherapeutics, Inc. - VP of IR & Public Relations

Thank you, operator. Good afternoon, and thank you for joining us. Speaking on today's call, we have Fred Vogt, our Interim President and Chief Executive Officer; Igor Bilinsky, our Chief Operating Officer; Jim Ziegler, our Senior Vice President, Commercial; Dr. Friedrich Finckenstein, our Chief Medical Officer; and Jean-Marc Bellemin, our Chief Financial Officer; Dr. Madan Jagasia, our Senior Vice President of Medical Affairs, is also on the call to participate in the question-and-answer session.

This afternoon, we issued a press release that can be found on our website at iovance.com, which includes the financial results for the 3

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot